Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 5, 2008, Pages 1721-1727

  Jordan, Robert ^a   Tien, Deborah ^a,d   Bolken, Tove C ^a   Jones, Kevin F ^a   Tyavanagimatt, Shanthakumar R ^a   Strasser, Josef ^b   Frimm, Annie ^c   Corrado, Michael L ^c   Strome, Phoebe G ^c   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

^b TransTech Pharma Inc   (United States)

^c SYNEOS HEALTH   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ST 246;

ADULT; ANALYTIC METHOD; ARTICLE; BACKACHE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NEUTROPENIA; NORMAL HUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FASTING; HUMANS; ISOINDOLES; METABOLIC CLEARANCE RATE; NEUTROPENIA; ORTHOPOXVIRUS;

EID: 42949107447     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01303-07     Document Type: Article

References (14)

1. Bailey, T. R., S. R. Rippin, E. Opsitnick, C. J. Burns, D. C. Pevear, M. S. Collett, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, E. R. Kern, K. A. Keith, D. Dai, G. Yang, D. Hruby, and R. Jordan. 2007. N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H) -yl)carboxamides: identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 50:1442-1444.
2. Bray, M. 2003. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antivir. Res. 58:101-114.
3. Charman, W. N., C. J. Porter, S. Mithani, and J. B. Dressman. 1997. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86:269-282.
4. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://www3.niaid. nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf.
5. Fenner, F., D. A. Henderson, I. Arita, Z. Jazek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
6. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271.
7. Henderson, D. A., T. V. Inglesby, J. G. Bartlett, M. S. Ascher, E. Eitzen, P. B. Jahrling, J. Hauer, M. Layton, J. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. Perl, P. K. Russell, and K. Tonat for the Working Group on Civilian Biodefense. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281:2127-2137.
8. Hooper, J. W., E. Thompson, C. Wilhelmsen, M. Zimmerman, M. A. Ichou, S. E. Steffen, C. S. Schmaljohn, A. L. Schmaljohn, and P. B. Jahrling. 2004. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78:4433-4443.
9. Huggins, J. W., D. F. Smee, M. Martinez, and M. Bray. 1998. Cidofovir (HPMPC) treatment of monkeypox. Antivir. Res. 37:A37.
10. Mortimer, P. P. 2003. Can postexposure vaccination against smallpox succeed? Clin. Infect. Dis. 36:622-629.
11. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
12. Sbrana, E., R. Jordan, D. E. Hruby, R. I. Mateo, S.-Y. Xiao, M. Siirin, P. C. Newman, A. P. A. Travassos da Rosa, and R. B. Tesh. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
13. Whitley, R. J. 2003. Smallpox: a potential agent of bioterrorism. Antivir. Res. 57:7-12.
14. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.